Review article: Optimising SVR and the management of haematological side effects of peginterferon/ribavirin antiviral therapy for HCV: The role of Epoetin,G-CSF and novel agents

Department of Hepatology, St James's Hospital, Dubin, Ireland.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.73). 02/2010; 31(9):929-37. DOI: 10.1111/j.1365-2036.2010.04269.x
Source: PubMed


Chronic hepatitis C is one of the leading causes for chronic liver disease globally. The past two decades have seen many advances in hepatitis C treatment. Despite these advances, side effects of treatment are common. Haematological complications of treatment can result in treatment cessation and suboptimal results. Recent data have suggested a role for epoetin/granulocyte colony stimulating factor (G-CSF) in optimizing sustained virological response (SVR).
To investigate the nature, frequency and management of haematological side effects in the treatment of chronic hepatitis C infection.
The terms hepatitis C, hepatitis C virus (HCV), treatment, side effects, interferon, peginterferon, ribavirin, anaemia, haemoglobin, neutropenia, thrombocytopenia, haematological, growth factor, erythropoietin and G-CSF were searched on MEDLINE for the period 1991-2009. References from selected articles were also included.
Haematological side effects such as anaemia, neutropenia and thrombocytopenia are frequent in anti-HCV treatment. The off-label use of haematological growth factors is common and effective.
Erythropoietic agents are effective in treating anaemia, preventing ribavirin dose reduction, improving patients' quality of life, but the effect on SVR is not fully elucidated. G-CSF is effective in raising absolute neutrophil count; however, neutropenic HCV-infected patients on combination treatment may not experience increased bacterial infections. Eltrombopag, a new oral thrombopoietin mimetic, may allow combination treatment in patients with thrombocytopenia.

Full-text preview

Available from:
  • Source
    • "Current standard care of treatment for chronic hepatitis C is based on the combination of subcutaneous pegylated interferon-α and oral nucleoside drug ribavirin. However, serious side effects and poor response rates render the development of novel anti-HCV therapy an urgent need [3,6]. Several clinical trials are currently progressing for specifically targeted antiviral therapies (STAT-C) inhibitors that target specific protein pockets to inhibit HCV functions, while additional trials proceed on compounds which target host cell proteins that the virus utilizes for its survival/replication [7,8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The RNA polymerase NS5B of Hepatitis C virus (HCV) is a well-characterised drug target with an active site and four allosteric binding sites. This work presents a workflow for virtual screening and its application to Drug Bank screening targeting the Hepatitis C Virus (HCV) RNA polymerase non-nucleoside binding sites. Potential polypharmacological drugs are sought with predicted active inhibition on viral replication, and with proven positive pharmaco-clinical profiles. The approach adopted was receptor-based. Docking screens, guided with contact pharmacophores and neural-network activity prediction models on all allosteric binding sites and MD simulations, constituted our analysis workflow for identification of potential hits. Steps included: 1) using a two-phase docking screen with Surflex and Glide Xp. 2) Ranking based on scores, and important H interactions. 3) a machine-learning target-trained artificial neural network PIC prediction model used for ranking. This provided a better correlation of IC50 values of the training sets for each site with different docking scores and sub-scores. 4) interaction pharmacophores-through retrospective analysis of protein-inhibitor complex X-ray structures for the interaction pharmacophore (common interaction modes) of inhibitors for the five non-nucleoside binding sites were constructed. These were used for filtering the hits according to the critical binding feature of formerly reported inhibitors. This filtration process resulted in identification of potential new inhibitors as well as formerly reported ones for the thumb II and Palm I sites (HCV-81) NS5B binding sites. Eventually molecular dynamics simulations were carried out, confirming the binding hypothesis and resulting in 4 hits.
    Full-text · Article · Nov 2012 · BMC Bioinformatics
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, a register smart move method performing placement-aware retiming and replication for sequential circuits implemented in field programmable gate arrays (FPGAs) is presented. This method integrates two major register move operations with circuit functionality unchanged. One operation moves registers across combinational components, called retiming. The other one moves registers across interconnect to reduce critical path delay. Register replication technique is used when the fanout of register to be moved is larger than one. Move budget is defined and used to guide the moves. An incremental placement is used to place retimed or replicated registers. Experiments show that the smart move method proposed in this paper can effectively reduce the path delay, achieving 16% in average of the maximum frequency for sequential circuits implemented in FPGAs.
    No preview · Conference Paper · Nov 2003
  • Source

    Preview · Article · Jan 2010
Show more